MIDF Research maintained its “buy’’ call with unchanged target price of 98 sen per share.
PETALING JAYA: Pharmaniaga Bhd
’s initiative of supplying vaccines out of Malaysia will see its business prospering beyond the local sector.
Its long-term prospects also remains positive and with the group’s other strategies in providing access to its pharmaceuticals as well as increasing capacities and capabilities.
Already a subscriber? Log in.
Subscribe or renew your subscriptions to win prizes worth up to RM68,000!
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
